UNSPSC 51111833: Axitinib

This classification denotes a tyrosine kinase inhibitor with the molecular formula C22H18N4OS, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier C9LVQ0YUXG. European Medicines Agency schedules axitinib in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB25427. The term AXITINIB is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 20, no. 3, 2006, list 56. ). Most nations schedule axitinib under HS 29333990 and SITC 51574.

As of Q4 2014, AXITINIB remains the US FDA Preferred Term for this commodity. Axitinib bears US NLM identifiers UMLS ID C1700874 and NCI Concept Code C38718. SMILES: S(C1CC2[NH]NC(C2CC1)/C=C/C1NCCCC1)C1C(CCCC1)C(=O)NC.

UNSPSC 51111833 Axitinib is a Commodity code for a targeted cancer therapy drug used in state and local government procurement, though the source provides no documentation of recent solicitation activity under this code. State and local health departments, corrections systems, public hospitals, and Medicaid programs may procure axitinib as part of oncology treatment protocols, but no recent opportunities block is present to ground this assessment in actual buying patterns or issuing-body mix.

Without posted RFP, RFQ, IFB, or ITB notices in the recent-opportunities record, no geographic concentration, repeat buyers, or representative solicitations can be identified. Monitor this code for activity if your firm supplies pharmaceutical products to state health systems or correctional facilities, but current market signals do not support near-term pursuit.